• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

AP20187 Inhibitor

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5754520

AP20187 (B/B Homodimerizer) is a cell-permeable ligand used to dimerize FK506-binding protein (FKBP) fusion proteins. And it initiate biological signaling cascades and gene expression or disrupt protein-protein interactions. More details

Please Inquire
Product Documentation
PDF
Sample Manual Insert View PDF
PDF
Testing Data View PDF
PDF
Certificate of Analysis (COA) View PDF
PDF
QC Report View PDF
PDF
Material Safety Data Sheet View PDF
PDF
Technical Datasheet View PDF
PDF
Protocol View PDF

Product Overview

Online Datasheet in PDF
Product Name
AP20187, Inhibitor
Full Product Name
AP20187
Product Gene Name
AP20187, inhibitor
Product Synonym Names
B/B Homodimerizer
Form/Format
Solid. Powder
Purity/Purification
98.00%
Preparation and Storage
Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent
Molecular Weight
1482.75
Solubility
DMSO: 57mg/mL (38.44mM)
(<1mg/ml refers to the product slightly soluble or insoluble)
Formula
C82H107N5O20
SMILES
COC1=C(OC)C=C(CC[C@H](C2=CC=CC(OCC(NCC(CN(C)C)CNC(COC3=CC=CC([C@H](OC([C@H]4N(C([C@@H](CC)C5=CC(OC)=C(OC)C(OC)=C5)=O)CCCC4)=O)CCC6=CC(OC)=C(OC)C=C6)=C3)=O)=O)=C2)OC([C@@H]7CCCCN7C([C@H](C8=CC(OC)=C(OC)C(OC)=C8)CC)=O)=O)C=C1
CAS Number
195514-80-8
Target & IC50
FKBP homodimerizer
In Vitro
AP20187 treatment,significantly alleviates EAE-induced myelin damage in these mice. AP20187 (B/B Homodimerizer) treatment,significantly reduces the number of degenerating axons and increases the density of axons in the demyelinating lesions in the lumbar spinal cord of PLP/Fv2E-PERK mice[2]. Real-time PCR analysis shows that AP20187 (B/B Homodimerizer) (0.5mg/kg, 2mg/kg, or 5mg/kg) treatment,significantly increases the levels of CHOP mRNA in the CNS of PLP/Fv2E-PERK mice at PID12.

Structure of AP20187, inhibitor

AP20187 Inhibitor – Cat# MBS5754520

Product References and Citations for AP20187, inhibitor

Ahmed S, et al. Photocleavable dimerizer for the rapid reversal of molecular trap antagonists. J Biol Chem. 2014 Feb 21;289(8):4546-52.
Ahmed S, et al. Photocleavable dimerizer for the rapid reversal of molecular trap antagonists. J Biol Chem. 2014 Feb 21;289(8):4546-52.
Lin W, et al. Oligodendrocyte-specific activation of PERK signaling protects mice against experimental autoimmune encephalomyelitis. J Neurosci. 2013 Apr 3;33(14):5980-91.
Lin W, et al. Oligodendrocyte-specific activation of PERK signaling protects mice against experimental autoimmune encephalomyelitis. J Neurosci. 2013 Apr 3;33(14):5980-91.
Haas ME, et al. The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Nephrotic Syndrome-Associated Hypercholesterolemia. Circulation. 2016 Jul 5;134(1):61-72.
Haas ME, et al. The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Nephrotic Syndrome-Associated Hypercholesterolemia. Circulation. 2016 Jul 5;134(1):61-72.

Other Notes

Small volumes of AP20187, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for AP20187 purchase

MBS5754520 is an inhibitor targeting AP20187.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000